TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.76 – $1.98
Volume35,222
Market cap$21M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$20.95M
Price / earnings
171.72×
Price / book
0.76×
Price / sales
5.59×
EV / sales
2.8×
EV / EBITDA
-3.18×
Profitability
Earnings per share
$0.01
Return on assets
0.32%
Return on equity
0.44%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.75×
Quick ratio
6.75×
Cash ratio
4.05×
Cash flow
Price / cash flow
6.29×
Price / free cash flow
6.29×
Free cash flow
$3.33M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TXMD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.26M
$869K
$724K
$893K
$784K
$952K
$393K
$667K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.26M
$869K
$724K
$893K
$784K
$952K
$393K
$667K
Selling, general and administrative
$1.64M
$1.58M
$1.35M
$2.29M
$1.52M
$1.55M
$1.49M
$1.21M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$1.74M
$1.69M
$1.45M
$2.45M
$1.65M
$1.65M
$1.67M
$1.32M
Operating income
-$479K
-$816K
-$723K
-$1.55M
-$862K
-$695K
-$1.28M
-$652K
Interest expense
$0
$0
$0
$7K
$0
$0
$0
$8K
Income before taxes
$501K
$164K
$103K
-$580K
$50K
$545K
-$668K
$83K
Income taxes
$0
$0
$0
$32K
$0
$0
-$32K
-$31K
Net income
$491K
$155K
$95K
-$619K
$152K
$551K
-$653K
$252K
Net income attributable to common shareholders
$491K
$155K
$95K
-$619K
$152K
$551K
-$653K
$252K
EBITDA
-$382K
-$721K
-$629K
-$1.58M
-$766K
-$599K
-$1.19M
-$1.81M
Basic earnings per share
$0.04
$0.01
$0.01
-$0.05
$0.01
$0.05
-$0.06
$0.02
Diluted earnings per share
$0.04
$0.01
$0.01
-$0.05
$0.01
$0.05
-$0.06
$0.02
Recent news
Company coverage with links to the original publishers.
The sexual wellness market is expected to grow at a CAGR of 4.7% by 2031, driven by increasing awareness of sexual health and the availability of a wide range of products. However, social stigma and regulatory challenges remain as key restraints.
TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) delivered earnings and revenue surprises of -33.33% and 3.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Gainers
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
IVERIC bio, Inc. (NASDAQ: ISEE) rose 66.3% to close at $15.70 on Tuesday after the company announced positive data from the second Phase 3 trial of Zimura (avacincaptad pegol) for geographic atrophy (GA).
HyreCar Inc. (NASDAQ: HYRE) climbed 58.1% to close at $1.27 on Tuesday after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist Partners.
Spero Therapeutics, Inc. (NASDAQ: SPRO) gained 55.5% to close at $1.13. Spero Therapeutics received minutes from a recent Type A meeting with the FDA, discussing steps required to resubmit the marketing application for tebipenem HBr for complicated urinary tract infection (cUTI).
ChannelAdvisor Corporation (NYSE: ECOM) shares jumped 55% to settle at $22.79 after the company announced it will be acquired by CommerceHub for $23.10 per share.
Akumin Inc. (NASDAQ: AKU) climbed 37% to close at $1.63. Akumin recently received notification letter from the Nasdaq confirming that company had regained compliance with minimum bid price requirement.
Apexigen, Inc. (NASDAQ: APGN) rose 34.4% to close at $7.03.
First Wave BioPharma, Inc. (NASDAQ: FWBI) shares gained 32.7% to close at $4.22 after gaining 7% on Friday.
Galera Therapeutics, Inc. (NASDAQ: GRTX) jumped 29.5% to settle at $1.67. Galera Therapeutics, last month, posted a Q2 loss of $0.54 per share.
HilleVax, Inc. (NASDAQ: HLVX) rose 24.8% to close at $17.05. HilleVax recently said Safety Data Monitoring Committee has recommended continuation of NEST-IN1 Phase 2b clinical trial.
T Stamp Inc. (NASDAQ: IDAI) gained 24.6% to close at $1.72.
Sunrise New Energy Co., Ltd. (NASDAQ: EPOW) jumped 24.6% to close at $3.49.
Avaya Holdings Corp. (NASDAQ: AVYA) gained 24% to close at $2.12.
Avalo Therapeutics, Inc. (NASDAQ: AVTX) rose 22.3% to settle at $5.87.
Avalo advanced BTLA agonist fusion protein (AVTX-008) to IND-enabling stage.
BioVie Inc. (NASDAQ: BIVI) rose 21.6% to close at $3.44.
Ainos, Inc. (NASDAQ: AIMD) gained 21.1% to close at $2.24. Ainos recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its drug candidate VELDONA, for treatment of mild symptoms related to COVID-19.
Neonode Inc. (NASDAQ: NEON) jumped 18.7% to settle at $4.26. Neonode, last month, posted a Q2 loss of $0.11 per share.
Grove Collaborative Holdings, Inc. (NYSE: GROV) gained 18.4% to close at $5.80.
a.k.a. Brands Holding Corp. (NYSE: AKA) surged 17.4% to settle at $2.36.
SelectQuote, Inc. (NYSE: SLQT) climbed 16.8% to settle at $1.11. SelectQuote recently said Q4 sales results were lower year-over-year and issued FY23 sales guidance below analyst estimates.
ADT Inc. (NYSE: ADT) rose 16.4% to close at $8.39 after the company announced it has secured investments totaling $1.5 billion from State Farm and Google.
Dermata Therapeutics, Inc. (NASDAQ: DRMA) gained 15.3% to close at $0.70. Dermata Therapeutics recently posted a Q2 loss of $0.24 per share
Regulus Therapeutics Inc. (NASDAQ: RGLS) gained 14.1% to close at $1.62. Regulus Therapeutics, last ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.